Taken together, these data highlight CpG sites within the MEG3 promotor region as potential prognostic factors for AML patient OS and suggest that DLK1-MEG3 imprinted gene dysregulation may explain this phenomenon. The gene discussed is DLK1; the disease is acute myeloid leukemia.